Format

Send to

Choose Destination
Clin Infect Dis. 2007 Jun 15;44(12):1543-8. Epub 2007 May 4.

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.

Author information

1
Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, CA, USA. polishmd@stanford.edu

Abstract

The efficacy of vancomycin for the treatment of patients with infections due to Staphylococcus aureus is impaired by its poor tissue penetration and by its relatively weak antibacterial activity--an activity that is declining as S. aureus evolves. Neither dose escalation nor use of vancomycin in combination with other antibiotics that have antistaphylcoccal activity has been demonstrated to safely enhance its therapeutic efficacy. Although no clinical trials suggest superiority of vancomycin over any comparator, some have provided evidence of its inferiority. Strong consideration should be given to the use of alternative agents in the treatment of serious S. aureus infections.

PMID:
17516396
DOI:
10.1086/518452
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center